Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIO trial of dual broadly neutralizing antibodies during analytical treatment interruption in early-treated HIV
NL-OMON59179Phase 2Recruiting
- Sponsor
- Imperial College London
- Start
- Oct 2025
- Modality
- Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Imperial College London. Primary endpoint: Time to viral rebound within 20 weeks after initial analytical treatment interruption. Started Oct 2025; status: recruiting.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON59179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59179.